Avenzo Therapeutics to Present AVZO-023 Data in December
The company will unveil preliminary Phase 1 clinical trial results during the San Antonio Breast Cancer Symposium.
Updated on Oct. 30, 2026 in Cancer
Avenzo Therapeutics is set to present preliminary Phase 1 results from its ORION-1 study of the drug candidate AVZO-023 on December 9, 2026. This presentation takes place during the annual San Antonio Breast Cancer Symposium in Texas.
Why it matters
The study evaluates AVZO-023 in combination with fulvestrant as a potential treatment for HR+/HER2- breast cancer. The drug aims to address tumor proliferation and resistance by specifically targeting CDK4 signaling pathways.
The preliminary clinical results will be featured as abstract number 2618 and presentation number P1-4-13. This study represents an early-stage investigation into the triplet combination of AVZO-023, AVZO-021, and fulvestrant.
The players
Avenzo Therapeutics
Avenzo Therapeutics is a biopharmaceutical company headquartered in San Diego that focuses on the development of novel cancer therapies.
The details
The results will be displayed as a poster at the Henry B. Gonzalez Convention Center during the symposium. Unlike broad-spectrum inhibitors, the drug is designed to inhibit CDK4 signaling while intentionally sparing CDK6.
Timeline
The San Antonio Breast Cancer Symposium is scheduled for December 8-11, 2026.
The presentation of preliminary study results occurs on December 9, 2026.
The Big Picture
The San Antonio Breast Cancer Symposium serves as the primary global forum for sharing new advancements in breast cancer research. This presentation marks a continuation of the symposium's role as the venue for unveiling preliminary data on emerging endocrine therapy combinations.
This development represents an early-stage research milestone and does not currently impact clinical treatment options for patients. Future data will clarify whether this selective CDK4 inhibition strategy offers a viable path forward for managing resistant breast cancer.
The takeaway
Clinical trials for new oncology drugs are long-term processes that begin with Phase 1 studies focused on safety and dosage. Investors and patients should view this upcoming presentation as an initial snapshot of the drug's activity before it proceeds to larger-scale validation.
Further reading
Learn more about the latest research and clinical developments in the field of Cancer.
Source note: This article includes information reported by Firstwordpharma.
